received Arexvy twice, once in 2023 and the second dose was given on 26Dec2024; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 65-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 52Z52, expiry date 16-OCT-2025) for prophylaxis. Previously administered products included Arexvy (received 1st dose in 2023). On 26-DEC-2024, the patient received the 2nd dose of Arexvy. On 26-DEC-2024, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: received Arexvy twice, once in 2023 and the second dose was given on 26Dec2024). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 03-JAN-2025 The patient received Arexvy twice, which led to an extra dose administered.